Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Latest Information Update: 26 Apr 2024
At a glance
- Drugs Olanzapine/samidorphan (Primary)
- Indications Bipolar I disorders; Schizophrenia
- Focus Adverse reactions
- Acronyms ENLIGHTEN-Youth Extension
- Sponsors Alkermes
- 21 Oct 2021 Status changed from not yet recruiting to recruiting.
- 06 Aug 2021 New trial record